Literature DB >> 26876940

Optimizing HCV treatment - Moving beyond the cost conundrum.

D Steven Fox1, Jeffrey S McCombs2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26876940     DOI： 10.1016/j.jhep.2016.02.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

Review 1.  Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population.

Authors:  Arun Rajasekaran; Ricardo A Franco; Edgar T Overton; Brendan M McGuire; Graham C Towns; Jayme E Locke; Deirdre L Sawinski; Emmy K Bell
Journal:  Kidney Int Rep       Date:  2021-04-25

2.  Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.

Authors:  Chao-Min Huang; Tsung-Hui Hu; Kuo-Chin Chang; Po-Lin Tseng; Sheng-Nan Lu; Chien-Hung Chen; Jing-Houng Wang; Chuan-Mo Lee; Ming-Chao Tsai; Ming-Tsung Lin; Yi-Hao Yen; Chao-Hung Hung; Chung-Lung Cho; Cheng-Kun Wu
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

3.  Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries.

Authors:  Jeah Jung; Roger Feldman; Yamini Kalidindi; Thomas Riley
Journal:  JAMA Netw Open       Date:  2020-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.